Tag: RHHBY

  • Why Need to Watch: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Merck & Co., Inc. (NYSE:MRK), Roche Holding (ADR) (OTCMKTS: RHHBY)

    On 12 JUNE VIVUS, Inc. (NASDAQ:VVUS) announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is -0.77%. On last trading day company shares ended up $5.17. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is 1.94%.

    On 13 JUNE Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it is programmed to present a corporate overview on Wednesday, June 18, 2014. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -1.27% in last trading session and ended the day on $6.20. ARNA Gross Margin is 93.70% and its return on assets is -8.10%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -6.06%.

    Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its Annual Meeting of Stockholders will be webcast live on June 25, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -1.16% in last trading session and was closed at $6.38, while trading in range of $6.34 – $6.46. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -6.45%.

    Merck & Co., Inc. (NYSE:MRK) made an official statement, revealing that it reached an agreement for the acquisition of Idenix Pharmaceuticals Inc. in a deal that is estimated to 3.85 billion dollars. The purchase will help the company to broaden its experimental pipeline for hepatitis C treatments. Merck & Co., Inc. (NYSE:MRK) ended the last trading day at $58.06. Company weekly volatility is calculated as 1.05% and price to cash ratio as 8.27. Merck & Co., Inc. (NYSE:MRK) showed a positive weekly performance of 0.02%.

    On 20 MAY Roche Holding Ltd. (ADR) (OTCMKTS: RHHBY) announced the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. Roche Holding Ltd. (ADR) (OTCMKTS: RHHBY) on last trading day company shares ended up $37.08.